Christina Mattina

Researchers have highlighted physician education as a potential solution for the opioid epidemic, based on their findings that attending a top-ranked medical school is associated with writing far fewer opioid prescriptions.

New research has identified a gene that enables paclitaxel to spread cancer to the lungs even as it shrinks tumors in the breast.

A new study indicates that drugs approved through the FDA’s expedited review programs offer larger health gains than those approved via the traditional review process.

Amidst news of Senator John McCain’s glioblastoma diagnosis, a recent discussion between 2 neuro-oncology researchers explored the reasons why this aggressive brain tumor is so difficult to manage, and outlined the ongoing investigations into possible therapies.

A recent study described why physicians find that deprescribing a patient's ongoing medication may be easier said than done.

In an effort to brainstorm strategies that will boost patient engagement in medical device development, the FDA has announced it will host the first meeting of its Patient Engagement Advisory Committee this fall.

After the Affordable Care Act (ACA) required private insurers to pay the standard-of-care costs for patients participating in approved clinical trials, the rate of patients cleared by their insurer to take part in early-phase oncology trials has increased, a new study has found.

According to a recent study, implementing cost sharing requirements on mental health services produced short-term savings by reducing mental health care use, but resulted in more costly outcomes like involuntary commitment and acute mental health treatment.

A survey designed to assess knowledge of prediabetes among primary care providers (PCPs) finds that their awareness of risk factors and management strategies is lower than ideal.

With Republicans unable to agree on legislation to repeal and replace the Affordable Care Act (ACA), the next step may be to work out some bipartisan fixes with Democrats. Here are 5 ideas that could appear in a bipartisan deal to fix the ACA.

When Donald Trump was elected president in November 2016, repealing the Affordable Care Act (ACA) suddenly became an attainable goal for Republicans in Congress. Here, we look back at the legislative twists and turns of ACA repeal efforts in 2017.

AstraZeneca announced that its immuno-oncology drug durvalumab, in combination with tremelimumab, failed to meet a progression-free survival endpoint in the MYSTIC trial in patients with metastatic non-small cell lung cancer (NSCLC).

During a panel hosted by the National Cancer Institute (NCI), patient advocates and survivorship experts discussed the strides made in the field of cancer survivorship research.

In a blog post that served as a follow-up to a March report on electronic access to medical information, the Government Accountability Office (GAO) analyzed the reasons people may not use their electronic health records (EHRs) even if they are able to access them.

Researchers have identified a cellular signaling pathway that when activated by mutations may prevent immune cells from infiltrating bladder tumors, thus making the cancer resistant to immune checkpoint inhibitors.

Deprescribing ongoing medications has been identified as a way to prevent adverse drug events and avoid unnecessary medication utilization, but a recent study found that physicians report a number of obstacles making it difficult for them to deprescribe in their practice.

A study on long-term remission of diffuse large B-cell lymphoma (DLBCL) shows that Kite Pharma’s anti-CD19 chimeric antigen receptor-T (CAR-T) cell treatment resulted in remission for up to 56 months.

CMS announced it will hold a meeting to gather input on potential models to pay for behavioral healthcare that would improve quality, expand access, and lower costs for beneficiaries.

In a webinar hosted by Carevive, researcher Ethan Basch, MD, MSc, discussed the findings of his recent study linking electronic patient-reported outcomes (PROs) to better survival outcomes for patients with cancer.

In a recently released position statement, the American Society of Clinical Oncology (ASCO) has outlined a pathway that would address the rising costs of cancer drugs in the United States.

The National Quality Forum (NQF) has issued a report detailing the results of its experiment with including social risk factors in its risk adjustment models for performance measures.

The FDA has approved neratinib (Nerlynx) for the extended adjuvant treatment of some forms of breast cancer, but recommends precautions against the common side effect of diarrhea.

According to a recent study, adding a stimulator of interferon genes (STING) agonist to rituximab for lymphoma can help provoke an immune response to the monoclonal antibody in patients who had shown resistance.

New research finds that having a retail health clinic nearby can make patients less likely to visit the emergency department for minor or preventable conditions.

A partnership of federal departments announced a coordinated takedown of hundreds of defendants accused of perpetrating schemes to defraud Medicare and illegally distributing opioids.

In response to a request from the FDA, the National Academies of Sciences, Engineering, and Medicine has issued a report outlining the current body of research on chronic pain and opioid use disorder, including recommendations on what steps the regulatory agency can take in response to the ongoing epidemic.

A new draft report from the Institute for Clinical and Economic Review (ICER) evaluates the evidence on the effectiveness and value of 3 drugs used to treat ovarian cancer.

The House of Representatives passed the FDA Reauthorization Act of 2017 with a voice vote, indicating the strong levels of bipartisan support for the bill that will reauthorize the user fee programs that fund the FDA.

Blinatumomab is now fully approved as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), following FDA assessment of new trial data on survival outcomes and its use in certain clinical subgroups.

A recent analysis of cancer incidence and mortality rates across America finds that while those in rural counties are less likely to get cancer, cancer-related mortality rates are higher than in more populous areas, and this disparity is increasing over time.